Fietze I, Bölcskei P L, Hörmann K, Lund R, Mayer G, Müller D, Peter J H, Rasche K, Rühle K H, Sanner B, Schmatzler R, Stammnitz A, Schläfke M E
Medizinische Klinik I. Schlafmedizinisches Zentrum, Charité, Berlin.
Med Klin (Munich). 1996 Dec 15;91(12):758-65.
The prevalence of the obstructive sleep apnea syndrome is about 5% in the entire population. The amount of treatment-indications grows for this particular sleep-related breathing disorder due to the increasing usage of diagnostic screening tests. In most cases, the positive-pressure ventilation, PPV (nCPAP, nBiPAP) is considered as a highly effective form of treatment, in comparison to other treating methods. The residential polysomnographic supervised adjustment of the treatment is optimally applied to most of the patients. Due to the increasing number of the treated patients, the reports about the appearance of short-termed side effects during the adjustment of the PPV become more frequent.
We report on 9 patients who showed complications during the initial stage of treatment. The most common one, during the nCPAP-therapy, was the increase of central apneas. Because of this complication, a rapid optimization of the respiratory pressure or a change to a nBiPAP-therapy was necessary in 5 of the patients. 2 of the patients showed cardiac arrhythmias, some of which were severe. One patient produced a remarkable central hypoventilation during the initial phase of a nCPAP-therapy. The nBiPAP-titration combined with right-heart-catheter monitoring could demonstrate in another patient a possible cardiac decompensation through an increased ventilatory pressure.
The risk of a positive-pressure ventilation is higher in patients with accompanying cardiac, pulmonary, neuropsychiatric and/or otorhinolaryngologic disorders. Considering the various predisposing factors of the patients we suggest an intensive apparative monitoring as well as stuff-supervision during the introduction to a respiratory treatment. If complications appear, a rapid improvement of the ventilatory pressure or a change to another respiratory treatment is indicated.
阻塞性睡眠呼吸暂停综合征在整个人口中的患病率约为5%。由于诊断筛查测试的使用增加,这种与睡眠相关的特定呼吸障碍的治疗指征数量也在增加。与其他治疗方法相比,在大多数情况下,正压通气(PPV,即nCPAP、nBiPAP)被认为是一种高效的治疗方式。对大多数患者而言,在家中进行多导睡眠图监测下的治疗调整是最佳选择。由于接受治疗的患者数量不断增加,关于PPV调整过程中出现短期副作用的报告也越来越频繁。
我们报告了9例在治疗初始阶段出现并发症的患者。在nCPAP治疗期间,最常见的并发症是中枢性呼吸暂停增加。由于这一并发症,5例患者需要迅速优化呼吸压力或改用nBiPAP治疗。2例患者出现心律失常,其中一些较为严重。1例患者在nCPAP治疗初始阶段出现明显的中枢性通气不足。在另一例患者中,nBiPAP滴定联合右心导管监测显示,通气压力增加可能导致心脏失代偿。
伴有心脏、肺部、神经精神和/或耳鼻喉疾病的患者接受正压通气的风险更高。考虑到患者的各种 predisposing因素,我们建议在开始呼吸治疗期间进行强化设备监测以及密切观察。如果出现并发症,应迅速改善通气压力或改用其他呼吸治疗方法。